A 2018 report estimates that mental health issues could cost the global economy $16 trillion between now and 2030. Psychedelic drugs are needed to mitigate those costs.
Understanding the drug approval process that leads to drug patents and drug licensing is of critical importance for successful investing in psychedelics.
Mydecine's new Scientific Advisor holds over 150 U.S. and international patents and will oversee Mydecine's mycology lab.
Cybin Corp is partnering with IntelGenx Corp to produce a new delivery system for pharmaceutical-grade psilocybin.
Inflation is rapidly eroding our purchasing power and consuming our wealth. Here is a powerful antidote for investors.
The Psychedelics Revolution. One part changing social attitudes. One part medical necessity. One part hard economics.